Department of Radiology, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
Ann Nucl Med. 2013 Aug;27(7):581-91. doi: 10.1007/s12149-013-0731-7. Epub 2013 Apr 30.
Whole-body positron emission tomography/computed tomography (PET/CT) with [(11)C]- and [(18)F]-labeled choline derivates has emerged as a promising molecular imaging modality for the evaluation of prostate cancer. (11)C- and (18)F-choline PET/CT are used successfully for restaging prostate cancer in patients with biochemical recurrence of disease after definitive therapy, especially when the serum prostate-specific antigen level is >1.0 ng/mL. (11)C- and (18)F-choline PET/CT have more limited roles for the initial staging of prostate cancer and for the detection of tiny lymph node metastases due to the low spatial resolution inherent to PET. Overall, these modalities are most useful in patients with a high pre-test suspicion of metastatic disease. The following is a review of the current clinical roles of (11)C- and (18)F-choline PET/CT in the management of prostate cancer.
全身正电子发射断层扫描/计算机断层扫描（PET/CT）结合 [(11)C]- 和 [(18)F]- 标记的胆碱衍生物已成为评估前列腺癌的一种很有前途的分子成像方式。(11)C- 和 (18)F-胆碱 PET/CT 成功地用于在明确治疗后疾病生化复发的患者中对前列腺癌进行再分期，尤其是当血清前列腺特异性抗原水平>1.0 ng/mL 时。由于 PET 固有的低空间分辨率，(11)C- 和 (18)F-胆碱 PET/CT 在前列腺癌的初始分期和检测微小淋巴结转移方面的作用更为有限。总的来说，这些方法在高度怀疑转移性疾病的患者中最有用。以下是 (11)C- 和 (18)F-胆碱 PET/CT 在前列腺癌治疗中的当前临床作用的综述。
